Comparative Human Bioavailability Study of Macrocrystalline Nitrofurantoin and Two Prolonged-Action Hydroxymethylnitrofurantoin Preparations
Authors:
- Pieter J.M. GuelenPGPieter J.M. Guelen
- Johannes B.J. BoeremaJBJohannes B.J. Boerema
- Tom B. VreeTVTom B. Vree
- 1 December 1988
- journal article
- clinical trial
- Published by SAGE Publications in Drug Intelligence & Clinical Pharmacy
- Vol. 22 (12) , 959-964
Abstract
This single-blind crossover study compared the human bioavailability of macrocrystalline nitrofurantoin (Furadantine MC) and two prolonged-action hydroxymethylnitrofurantoin formulations (Urfadyn PL, bid, and Uridurine, tid), based on plasma nitrofurantoin concentrations and urinary nitrofurantoin excretion. The drugs were administered to 16 healthy females for a single day according to the recommended daily dosages. For comparison, Furadantine MC was administered both at the qid dosage recommended by the manufacturer and at tid dosage. Pharmacokinetic parameters determined were maximum plasma concentration after first dose, minimum plasma concentration after first dose, area under the plasma concentration-time curve (AUC), cumulative renal excretion over 30 hours (ARE), overall renal clearance, total body clearance, and bioavailability relative to Furadantine MC qid, based on plasma AUC (F) and ARE (F ren ). F for Furadantine MC 100 mg tid was 108 ± 25 percent (mean ± SD); for Uridurine 100 mg tid and Urfadyn PL 100 mg bid, F equalled 86 ± 33 percent and 53 ± 20 percent (pren for Furadantine MC 100 mg qid and the respective F ren of Furadantine MC 100 mg tid, Uridurine 100 mg tid, and Urfadyn PL 100 mg bid. No significant difference was found between the respective F and F ren of each of the drugs studied. Although bioavailability was comparable for Furadantine MC tid and qid, the single-day design of these studies precludes inferring that these dosage schedules are therapeutically equivalent. However, the significantly lower relative bioavailabilities for the prolonged-action hydroxymethylnitrofurantoin formulations suggest that Urfadyn PL 100 mg bid and Uridurine 100 mg tid are not pharmacokinetically equivalent to Furadantine MC.Keywords
This publication has 9 references indexed in Scilit:
- Nitrofurantoin dispositionClinical Pharmacology & Therapeutics, 1981
- Control of release and biological availability of drugs ? investigations into the renal elimination of nitrofurantoinInternational Journal of Pharmaceutics, 1981
- Rapid in vitro and in vivo conversion of hydroxymethyl-nitrofurantoin into nitrofurantoin as measured by HPLCInternational Journal of Pharmaceutics, 1979
- Determination of nitrofurantoin (Furadantine®) and hydroxymethylnitro-furantoin (Urfadyn®) in plasma and urine of man by means of high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1979
- The Pharmacokinetics of Nitrofurantoin and its Related Bioavailability1978
- The influence of food on nitrofurantoin bioavailabilityClinical Pharmacology & Therapeutics, 1976
- Bioavailability of 14 Nitrofurantoin ProductsJournal of Pharmaceutical Sciences, 1974
- Effect of food on nitrofurantoin absorptionClinical Pharmacology & Therapeutics, 1974
- Crystalline and Macrocrystalline Nitrofurantoin in the Treatment of Urinary-Tract InfectionNew England Journal of Medicine, 1974